Relmada (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated IND filing timelines (end of 2026 for both programs) and the quantified cash runway through 2029, which affect near-term financing and probability-weighted development timelines.
Market read
Traders can update development-timeline expectations and financing risk based on end-2026 IND guidance and a cash runway through 2029, ahead of Phase 3 data in first half of 2027.
What to watch
The call emphasizes manufacturing scheduling constraints and delivery-system finalization, which can be the real near-term failure points even if FDA alignment is said to be secured.
Background
Relmada is advancing lead intravesical candidates NDV-01 and sepranolone through FDA IND processes and toward a Phase 3 RESCUE registrational program.
Ticker impact
Relmada guided IND filings for NDV-01 and sepranolone by end of 2026 and said cash of $217.7M funds operations through 2029.
Moderate positive bias for the next days to weeks, with volatility around any subsequent IND/manufacturing updates.
The call provides concrete, time-bound milestones (IND by end-2026) and quantified liquidity (runway through 2029), which can re-rate probability-weighted timelines, but it is not yet clinical readout or regulatory clearance.
Market effects
Highlights manufacturing scale-up and delivery-system readiness as key gating items for intravesical oncology programs.
Primarily US biotech sentiment given NMIBC prevalence framing and FDA IND pathway focus.
Global PWS prevalence is mentioned, but the disclosed near-term catalysts are FDA-tied IND and US trial execution.
Counterpoint
Cash runway and IND timing may not offset dilution or execution risk if manufacturing schedule slots slip again.
Key entities
- companyRelmada Therapeutics
Subject of the earnings call transcript, providing cash, expense, and updated IND and Phase 3 RESCUE execution timelines.
- product_candidateNDV-01
Lead intravesical candidate with Phase 2 complete response and a Phase 3 RESCUE registrational program; IND filing expected by end of 2026.
- product_candidatesepranolone
Intravesical candidate with IND filing expected by end of 2026, pending finalization of a pre-filled syringe delivery system.
- manufacturing_partnerPiramal
Manufacturing partner for scalable GMP production of NDV-01.
